Nurix Therapeutics (NRIX) Operating Expenses (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Operating Expenses data on file, last reported at $98.7 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $98.7 million, up 21.43% year-over-year; the trailing twelve-month figure through Feb 2026 was $387.1 million (up 34.83% YoY), and the FY2025 annual result was $369.6 million, up 38.15% from the prior year.
• Operating Expenses improved to $98.7 million in Q1 2026 per NRIX's latest filing, from $96.7 million in the prior quarter.
• Over five years, Operating Expenses peaked at $99.3 million in Q3 2025 and troughed at $52.4 million in Q1 2022.
• A 5-year average of $70.0 million and a median of $60.6 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses surged 77.31% in 2022, then grew 0.51% in 2023.
• A 5-year view of Operating Expenses shows it stood at $55.5 million in 2022, then advanced by 9.05% to $60.5 million in 2023, then gained by 28.84% to $77.9 million in 2024, then climbed by 24.03% to $96.7 million in 2025, then increased by 2.15% to $98.7 million in 2026.
• Business Quant data shows NRIX's Operating Expenses at $98.7 million in Q1 2026, $96.7 million in Q4 2025, and $99.3 million in Q3 2025.